ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Research Rheum

Barbara Volcker Center Marks 20 Years of Research & Clinical Work

Catherine Kolonko  |  January 19, 2018

Although two decades have ticked by, rheumatologist Michael Lockshin, MD, MACR, still remembers the enlightening nature of many conversations he had with his curious and persistent patient Barbara Volcker, the wife of former U.S. Federal Reserve Chairman Paul Volcker. “The conversations we had at that time led to the mission of the Barbara Volcker Center,”…

Bimekizumab Improves Joint & Skin Symptoms in PsA Patients

Michele B. Kaufman, PharmD, BCGP  |  January 16, 2018

Preliminary results from an ongoing study show that bimekizumab improves joint and skin symptoms in patients with psoriatic arthritis…

Pedometers & RA: Does Increasing Physical Activity Decrease Fatigue?

Arthritis Care & Research  |  January 2, 2018

Recent research examined the effectiveness of a pedometer-based intervention for managing fatigue in patients with rheumatoid arthritis (RA). During the 21-week trial, RA patients using pedometers successfully increased their physical activity, with a greater than 30% decrease in the proportion of participants classified as sedentary. Patients also decreased their reported fatigue, and some reported improvements in function, pain, depressive symptoms and disease activity levels…

Developing & Leading a Research Team

Karen Appold  |  December 29, 2017

Translational research is designed to investigate a particular disease process to achieve an improved outcome for patients. Here are some insights into how to bring together the right people for a research team and keep that team focused…

Rituximab Use Increasing in Treatment of Pediatric Vasculitis

Catherine Kolonko  |  December 20, 2017

According to a large cohort study of pediatric patients, rituximab use is on the rise in the treatment of children diagnosed with vasculitis. Treatment with cyclophosphamide remains common, but it’s beginning to wane. Dialysis and mechanical ventilation also remain common, the study indicates. The retrospective study of hospitalized children in the U.S. included the largest…

Rheumatology Research Foundation Hosts Student, Resident Experience at ACR/ARHP Annual Meeting

From the College  |  December 20, 2017

On Nov. 5, more than 100 students and residents gathered for the Rheumatology Research Foundation’s Student and Resident Experience at the ACR/ARHP Annual Meeting in San Diego. As part of the Foundation’s work to increase the number of rheumatology professionals in the U.S., the event is designed to increase excitement in the field. Attendees enjoyed…

Weight Change in Early RA & the Risk of Mortality

Arthritis & Rheumatology  |  December 20, 2017

Sparks et al set out to investigate whether weight change during the early RA period is associated with subsequent mortality and to evaluate whether there is an RA-specific effect. They investigated weight change during the early RA period, because this is the window of time during which weight change is most likely to be related to RA-specific processes. They found that severe weight loss during the early RA period was associated with a subsequent increased mortality risk both for women with and without RA…

Does MRI Differentiate Osteoarthritis and Meniscal Tear in Knee Pain?

Kelly April Tyrrell  |  December 19, 2017

When a young patient arrives at a clinic complaining of knee pain with clicking or popping, a meniscal tear is often the culprit. “In young [people], there’s a pretty classic presentation of meniscal tear, with clicking and other mechanical symptoms, because the tear rubs up against different tissues,” says Jeffrey Katz, MD, MSc, a rheumatologist…

Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

Nan Yang, PharmD, & Kurt Oelke, MD, on behalf of the ARHP Practice Committee  |  December 19, 2017

Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab

Michele B. Kaufman, PharmD, BCGP  |  December 19, 2017

Bisphosphonate Drug Holidays Drug holidays are common for patients on bisphosphonate therapy. Often, these breaks in treatment are related to known U.S. Food and Drug Administration (FDA) warnings and drug class adverse effects. Currently, data on fracture risk related to drug holidays are limited. In recent research highlighted at the 2017 ACR/ARHP Annual Meeting ,…

  • « Previous Page
  • 1
  • …
  • 39
  • 40
  • 41
  • 42
  • 43
  • …
  • 129
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences